Uromune® (MV140)

About Inmunotek

Inmunotek is a privately held, revenue-generating biopharmaceutical company with a 30+ year legacy, founded on clinical laboratory roots. It has established itself as a commercial leader in allergy immunotherapy, with a broad portfolio of approved products and a growing pipeline that includes a notable bacterial vaccine candidate for recurrent urinary tract infections. The company is recognized for its innovation, receiving Spain's National Innovation Award, and operates with a fully integrated model from R&D to global commercialization, supported by a team of over 300 employees.

Therapeutic Areas